

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) July 29, 2010

---

**BECTON, DICKINSON AND COMPANY**

(Exact Name of Registrant as Specified in Its Charter)

---

**New Jersey**

(State or Other Jurisdiction of Incorporation)

---

**001-4802**

(Commission File Number)

---

**22-0760120**

(IRS Employer Identification No.)

---

**1 Becton Drive, Franklin Lakes, New Jersey**

(Address of Principal Executive Offices)

---

**07417-1880**

(Zip Code)

---

**(201) 847-6800**

(Registrant's Telephone Number, Including Area Code)

---

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On July 29, 2010, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for its third fiscal quarter ending June 30, 2010. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles ("non-GAAP measures"), as follows:

- Revenues. We present international and total revenue growth rates (for the total company and each of its business segments and units, and for our safety-engineered devices) for the third quarter and first nine months of fiscal year 2010 after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that this allows investors to better understand the underlying operating results of BD and facilitates comparisons to prior periods.
- Earnings Per Share from Continuing Operations. We present our diluted earnings per share from continuing operations ("EPS") for the first nine months of fiscal year 2010 after eliminating the non-cash charge related to health care reform impacting Medicare Part D reimbursements. We also present our EPS for the third quarter and first nine months of fiscal year 2009 after excluding the tax benefit relating to various tax settlements, and our EPS for the full 2009 fiscal year after excluding this tax benefit and the impact of the charge relating to our pending settlement of certain antitrust class action suits. These items are not considered by management to be part of ordinary operations. Accordingly, we believe that these adjusted measures of EPS are more indicative of BD's underlying performance for these periods, and allows investors to more easily compare BD's performance for these periods and to better understand BD's EPS guidance for fiscal year 2010.

We also present our growth in adjusted EPS for the third quarter and first nine months of fiscal year 2010, and our EPS guidance for the full 2010 fiscal year, after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD, and facilitates comparisons to the prior year periods.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

---

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated July 29, 2010, which is furnished pursuant to Item 2.02

Exhibit 99.2 Reconciliation of non-GAAP financial measures, which is furnished pursuant to Item 2.02

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Dean J. Parnicas  
Dean J. Parnicas  
Vice President, Corporate  
Secretary and Public Policy

Date: July 29, 2010

---

Exhibit Index

- 99.1 Press release dated July 29, 2010, which is furnished pursuant to Item 2.02
- 99.2 Reconciliation of non-GAAP financial measures, which is furnished pursuant to Item 2.02

1 Becton Drive  
Franklin Lakes, NJ 07417  
www.bd.com

News Release



Contact:

Sherry L. Bertner, Investor Relations - 201-847-5453  
Colleen T. White, Corporate Communications - 201-847-5369

**BD ANNOUNCES RESULTS FOR THIRD QUARTER FISCAL 2010**

- Reports earnings per share from continuing operations of \$1.29, in line with the Company's expectations;
- Expects full fiscal year 2010 earnings per share from continuing operations, excluding specified items, to increase 3 to 4 percent, or about 9 percent on a foreign currency-neutral basis, which is in line with previously communicated guidance of 8 to 10 percent. On a reported basis, earnings per share from continuing operations are expected to increase about 3 percent.
- Previously announced agreement to sell certain assets of the BD Medical segment remains on track to close in the fourth quarter fiscal 2010; results were not classified as discontinued operations for third quarter fiscal 2010.

**Franklin Lakes, NJ (July 29, 2010)** - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$1.878 billion for the third fiscal quarter ended June 30, 2010, representing an increase of 3.2 percent from the prior-year period, or 3.9 percent on a foreign currency-neutral basis.

---

“We are pleased with our results this quarter, with each of our three segments contributing to our growth. We delivered earnings per share from continuing operations of \$1.29, which is in line with the Company’s expectations,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “Despite the challenging global economy, we expect to deliver bottom-line growth of approximately 9 percent foreign-currency neutral, which is in line with our previously communicated range of 8 to 10 percent for the full fiscal year 2010. Profits and cash flows continue to improve as a result of operational efficiencies. We are also pleased to announce that we are increasing our share repurchases to \$700 million from \$550 million, which supports our ongoing commitment to return value to shareholders.”

**Update on the Sale of Certain Assets in the BD Medical Segment**

In May 2010, the Company signed agreements to sell certain assets of its BD Medical segment, including the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms of the Medical Surgical Systems unit. For the full fiscal year 2010, revenues and earnings per share associated with these asset groups were estimated at \$200 million and \$0.20, respectively. The results of operations associated with these asset groups have not been classified as discontinued operations in the accompanying financial tables as the criteria for such classification were not met in the third fiscal quarter 2010. The Company expects to record a gain on the sale in the fourth fiscal quarter 2010, when the transaction is expected to be completed.

**Third Quarter and Nine-Month Fiscal Year 2010 Operating Results**

Reported diluted earnings per share from continuing operations for the third quarter were \$1.29, compared with \$1.38 in the prior-year period, representing a 6.5 percent decrease. The prior-year period included a \$20 million, or \$0.08 per share, tax benefit related to various tax settlements in

---

multiple jurisdictions. Excluding this item, adjusted diluted earnings per share from continuing operations were \$1.30. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the third quarter increased by 6.9 percent.

For the nine-month period ending June 30, 2010, reported diluted earnings per share from continuing operations were \$3.81, compared with \$3.67 in the prior-year period, representing an increase of 3.8 percent. Current year-to-date results include a non-cash charge of \$8.9 million, or \$0.04 per share from continuing operations related to healthcare reform impacting Medicare Part D reimbursements, and the prior-year period included the aforementioned tax benefit of \$0.08 and a litigation charge of \$45 million, or \$0.11 per share. Excluding these items, adjusted diluted earnings per share from continuing operations increased by 4.1 percent to \$3.85, compared with \$3.70 adjusted earnings per share in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the nine-month period increased 11.4 percent.

#### **Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$993 million, representing an increase of 2.5 percent compared with the prior-year period, or 2.7 percent on a foreign currency-neutral basis. Revenues reflected solid sales of Diabetes Care products, which were partially offset by softer Pharmaceutical Systems revenues due to timing of orders in the quarter. The comparison to prior year is also negatively impacted by about 1 percentage point due to the H1N1 flu pandemic in fiscal year 2009. For the nine-month period ended June 30, 2010, BD Medical revenues increased 9.3 percent, or 7.6 percent on a foreign currency-neutral basis.

---



In the BD Diagnostics segment, worldwide revenues for the quarter were \$576 million, representing an increase of 1.7 percent compared with the prior-year period, or 2.0 percent on a foreign currency-neutral basis. Economic pressures in the U.S., resulting in reduced physician office visits, and reduced diagnostic volumes in Europe were the primary headwinds in the quarter. The comparison to prior year is also negatively impacted by 1.6 percentage points due to the H1N1 flu pandemic in fiscal year 2009. For the nine-month period ended June 30, 2010, BD Diagnostics revenues increased 4.9 percent, or 4.3 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$309 million, representing an increase of 8.4 percent compared with the prior-year period. Revenues increased 11.6 percent on a foreign currency-neutral basis, primarily driven by cell analysis instrument and reagent sales in the U.S., supplemental funding in Japan and a favorable comparison versus the prior-year period. For the nine-month period ended June 30, 2010, BD Biosciences revenues increased 4.7 percent, or 7.3 percent on a foreign currency-neutral basis.

### **Geographic Results**

Third quarter revenues in the U.S. were \$830 million, representing an increase of 3.0 percent from the prior-year period. Revenues outside of the U.S. were \$1.049 billion, representing an increase of 3.3 percent compared with the prior-year period, or 4.6 percent on a foreign currency-neutral basis. Revenues reflected continuing strength in emerging markets, which was offset by slower growth in Europe. For the nine-month period ended June 30, 2010, revenues in the U.S. were \$2.513 billion, representing an increase of 6.3 percent compared with the prior-year period. Revenues outside of the U.S. were \$3.127 billion, representing an increase of 7.9 percent compared with the prior-year period, or 6.7 percent on a foreign currency-neutral basis.

---

**Fiscal 2010 Outlook**

We expect reported revenues for the full year fiscal 2010 to increase approximately 5 percent, which is one percentage point less than previously communicated guidance, mainly driven by a weaker Euro and overall lower lab testing in the U.S. On a foreign currency-neutral basis, we expect revenues to increase 5 to 6 percent, as compared to our previously communicated guidance of about 6 percent, reflecting the lower lab testing and hospital demand.

We also expect reported diluted earnings per share from continuing operations for the full year fiscal 2010 to increase about 3 percent from \$4.92 in fiscal year 2009. Excluding the aforementioned charge of \$0.04 related to healthcare reform impacting Medicare Part D reimbursements, we expect diluted earnings per share from continuing operations for the full year fiscal 2010 will increase 3 to 4 percent, or about 9 percent on a foreign currency-neutral basis, which is in line with our previously communicated guidance. This is compared with adjusted diluted earnings per share from continuing operations, excluding the litigation charge of \$0.11 and the tax benefit adjustment of \$0.08, of \$4.95 for fiscal year 2009.

**Conference Call Information**

A conference call regarding BD's third quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 10:00 a.m. (ET) Thursday, July 29, 2010. The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on Thursday, August 5, 2010, access code 85449987.

---

### **Non-GAAP Financial Measures**

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non- GAAP measures to the comparable GAAP measures are included in the attached financial tables and the Form 8-K that BD filed today with the SEC.

### **About BD**

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*

*This press release, including the section entitled "Fiscal 2010 Outlook", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our*

---

*ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.*

---

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2010	Three Months Ended June 30, 2009	% Change
REVENUES	\$1,878,229	\$1,820,255	3.2
Cost of products sold	905,822	860,063	5.3
Selling and administrative	423,684	429,940	(1.5)
Research and development	108,623	98,489	10.3
TOTAL OPERATING COSTS AND EXPENSES	1,438,129	1,388,492	3.6
OPERATING INCOME	440,100	431,763	1.9
Interest income	2,094	12,767	(83.6)
Interest expense	(13,085)	(11,288)	15.9
Other income (expense), net	1,348	(4,247)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	430,457	428,995	0.3
Income tax provision	124,174	90,291	37.5
INCOME FROM CONTINUING OPERATIONS	306,283	338,704	(9.6)
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(619) AND \$214, RESPECTIVELY	625	2,323	(73.1)
NET INCOME	\$ 306,908	\$ 341,027	(10.0)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.31	\$ 1.41	(7.1)
Income from discontinued operations	\$ 0.00	\$ 0.01	NM
Net income (1)	\$ 1.32	\$ 1.42	(7.0)
Diluted:			
Income from continuing operations	\$ 1.29	\$ 1.38	(6.5)
Income from discontinued operations	\$ 0.00	\$ 0.01	NM
Net income	\$ 1.29	\$ 1.39	(7.2)
AVERAGE SHARES OUTSTANDING			
Basic	233,242	240,109	
Diluted	238,319	245,696	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2010	Nine Months Ended June 30, 2009	% Change
REVENUES	\$5,639,857	\$5,263,141	7.2
Cost of products sold	2,712,259	2,485,687	9.1
Selling and administrative	1,300,958	1,272,318	2.3
Research and development	310,025	294,391	5.3
TOTAL OPERATING COSTS AND EXPENSES	4,323,242	4,052,396	6.7
OPERATING INCOME	1,316,615	1,210,745	8.7
Interest income	20,535	18,730	9.6
Interest expense	(38,985)	(26,607)	46.5
Other expense, net	(843)	(538)	56.7
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,297,322	1,202,330	7.9
Income tax provision	377,336	295,033	27.9
INCOME FROM CONTINUING OPERATIONS	919,986	907,297	1.4
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(519) AND \$1,681, RESPECTIVELY	929	7,086	(86.9)
NET INCOME	\$ 920,915	\$ 914,383	0.7
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 3.91	\$ 3.77	3.7
Income from discontinued operations	\$ 0.00	\$ 0.03	NM
Net income	\$ 3.91	\$ 3.80	2.9
Diluted:			
Income from continuing operations	\$ 3.81	\$ 3.67	3.8
Income from discontinued operations	\$ 0.00	\$ 0.03	NM
Net income (1)	\$ 3.82	\$ 3.70	3.2
AVERAGE SHARES OUTSTANDING			
Basic	235,316	240,923	
Diluted	241,151	247,083	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	2010	Three Months Ended June 30, 2009	% Change
<b>BD MEDICAL</b>			
United States	\$ 401,965	\$ 397,898	1.0
International	590,875	570,773	3.5
<b>TOTAL</b>	<b>\$ 992,840</b>	<b>\$ 968,671</b>	<b>2.5</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 303,521	\$ 299,374	1.4
International	272,748	267,005	2.2
<b>TOTAL</b>	<b>\$ 576,269</b>	<b>\$ 566,379</b>	<b>1.7</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 124,146	\$ 108,136	14.8
International	184,974	177,069	4.5
<b>TOTAL</b>	<b>\$ 309,120</b>	<b>\$ 285,205</b>	<b>8.4</b>
<b>TOTAL REVENUES</b>			
United States	\$ 829,632	\$ 805,408	3.0
International	1,048,597	1,014,847	3.3
<b>TOTAL</b>	<b>\$1,878,229</b>	<b>\$1,820,255</b>	<b>3.2</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	2010	Nine Months Ended June 30, 2009	% Change
<b>BD MEDICAL</b>			
United States	\$1,254,592	\$1,167,062	7.5
International	1,723,954	1,558,285	10.6
<b>TOTAL</b>	<b>\$2,978,546</b>	<b>\$2,725,347</b>	<b>9.3</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 906,566	\$ 872,055	4.0
International	820,849	774,156	6.0
<b>TOTAL</b>	<b>\$1,727,415</b>	<b>\$1,646,211</b>	<b>4.9</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 351,933	\$ 325,926	8.0
International	581,963	565,657	2.9
<b>TOTAL</b>	<b>\$ 933,896</b>	<b>\$ 891,583</b>	<b>4.7</b>
<b>TOTAL REVENUES</b>			
United States	\$2,513,091	\$2,365,043	6.3
International	3,126,766	2,898,098	7.9
<b>TOTAL</b>	<b>\$5,639,857</b>	<b>\$5,263,141</b>	<b>7.2</b>



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended June 30,  
(Unaudited; Amounts in thousands)

	United States		% Change
	2010	2009	
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$252,438	\$256,171	(1.5)
Diabetes Care	96,071	91,330	5.2
Pharmaceutical Systems	45,824	43,460	5.4
Ophthalmic Systems	7,632	6,937	10.0
<b>TOTAL</b>	<b>\$401,965</b>	<b>\$397,898</b>	<b>1.0</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$159,228	\$155,760	2.2
Diagnostic Systems	144,293	143,614	0.5
<b>TOTAL</b>	<b>\$303,521</b>	<b>\$299,374</b>	<b>1.4</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 84,365	\$ 70,518	19.6
Discovery Labware	39,781	37,618	5.7
<b>TOTAL</b>	<b>\$124,146</b>	<b>\$108,136</b>	<b>14.8</b>
<b>TOTAL UNITED STATES</b>	<b>\$829,632</b>	<b>\$805,408</b>	<b>3.0</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended June 30, (continued)  
(Unaudited; Amounts in thousands)

			International		
	2010	2009	Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 267,461	\$ 242,701	10.2	7.4	2.8
Diabetes Care	101,081	94,521	6.9	7.2	(0.3)
Pharmaceutical Systems	208,993	220,503	(5.2)	(1.6)	(3.6)
Ophthalmic Systems	13,340	13,048	2.2	7.1	(4.9)
<b>TOTAL</b>	<b>\$ 590,875</b>	<b>\$ 570,773</b>	<b>3.5</b>	<b>3.9</b>	<b>(0.4)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 144,298	\$ 136,427	5.8	5.9	(0.1)
Diagnostic Systems	128,450	130,578	(1.6)	(0.5)	(1.1)
<b>TOTAL</b>	<b>\$ 272,748</b>	<b>\$ 267,005</b>	<b>2.2</b>	<b>2.7</b>	<b>(0.5)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 146,068	\$ 139,251	4.9	10.5	(5.6)
Discovery Labware	38,906	37,818	2.9	6.8	(3.9)
<b>TOTAL</b>	<b>\$ 184,974</b>	<b>\$ 177,069</b>	<b>4.5</b>	<b>9.7</b>	<b>(5.2)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$1,048,597</b>	<b>\$1,014,847</b>	<b>3.3</b>	<b>4.6</b>	<b>(1.3)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended June 30, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	Total		
			Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 519,899	\$ 498,872	4.2	2.8	1.4
Diabetes Care	197,152	185,851	6.1	6.2	(0.1)
Pharmaceutical Systems	254,817	263,963	(3.5)	(0.4)	(3.1)
Ophthalmic Systems	20,972	19,985	4.9	8.1	(3.2)
<b>TOTAL</b>	<b>\$ 992,840</b>	<b>\$ 968,671</b>	<b>2.5</b>	<b>2.7</b>	<b>(0.2)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 303,526	\$ 292,187	3.9	3.9	—
Diagnostic Systems	272,743	274,192	(0.5)	—	(0.5)
<b>TOTAL</b>	<b>\$ 576,269</b>	<b>\$ 566,379</b>	<b>1.7</b>	<b>2.0</b>	<b>(0.3)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 230,433	\$ 209,769	9.9	13.6	(3.7)
Discovery Labware	78,687	75,436	4.3	6.3	(2.0)
<b>TOTAL</b>	<b>\$ 309,120</b>	<b>\$ 285,205</b>	<b>8.4</b>	<b>11.6</b>	<b>(3.2)</b>
<b>TOTAL REVENUES</b>	<b>\$1,878,229</b>	<b>\$1,820,255</b>	<b>3.2</b>	<b>3.9</b>	<b>(0.7)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Nine Months Ended June 30,  
(Unaudited; Amounts in thousands)

	United States		% Change
	2010	2009	
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 787,574	\$ 754,776	4.3
Diabetes Care	285,150	263,028	8.4
Pharmaceutical Systems	159,923	129,177	23.8
Ophthalmic Systems	21,945	20,081	9.3
<b>TOTAL</b>	<b>\$1,254,592</b>	<b>\$1,167,062</b>	<b>7.5</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 465,395	\$ 452,426	2.9
Diagnostic Systems	441,171	419,629	5.1
<b>TOTAL</b>	<b>\$ 906,566</b>	<b>\$ 872,055</b>	<b>4.0</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 240,152	\$ 219,668	9.3
Discovery Labware	111,781	106,258	5.2
<b>TOTAL</b>	<b>\$ 351,933</b>	<b>\$ 325,926</b>	<b>8.0</b>
<b>TOTAL UNITED STATES</b>	<b>\$2,513,091</b>	<b>\$2,365,043</b>	<b>6.3</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Nine Months Ended June 30, (continued)  
(Unaudited; Amounts in thousands)

	International				
	2010	2009	Reported	% Change FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 798,440	\$ 697,178	14.5	9.7	4.8
Diabetes Care	301,508	271,221	11.2	8.1	3.1
Pharmaceutical Systems	583,251	550,718	5.9	5.0	0.9
Ophthalmic Systems	40,755	39,168	4.1	5.3	(1.2)
<b>TOTAL</b>	<b>\$1,723,954</b>	<b>\$1,558,285</b>	<b>10.6</b>	<b>7.6</b>	<b>3.0</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 425,967	\$ 396,380	7.5	5.3	2.2
Diagnostic Systems	394,882	377,776	4.5	3.9	0.6
<b>TOTAL</b>	<b>\$ 820,849</b>	<b>\$ 774,156</b>	<b>6.0</b>	<b>4.6</b>	<b>1.4</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 464,091	\$ 450,615	3.0	7.1	(4.1)
Discovery Labware	117,872	115,042	2.5	5.8	(3.3)
<b>TOTAL</b>	<b>\$ 581,963</b>	<b>\$ 565,657</b>	<b>2.9</b>	<b>6.8</b>	<b>(3.9)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$3,126,766</b>	<b>\$2,898,098</b>	<b>7.9</b>	<b>6.7</b>	<b>1.2</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Nine Months Ended June 30, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	Total		
			Reported	% Change FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$1,586,014	\$1,451,954	9.2	6.9	2.3
Diabetes Care	586,658	534,249	9.8	8.2	1.6
Pharmaceutical Systems	743,174	679,895	9.3	8.5	0.8
Ophthalmic Systems	62,700	59,249	5.8	6.6	(0.8)
<b>TOTAL</b>	<b>\$2,978,546</b>	<b>\$2,725,347</b>	<b>9.3</b>	<b>7.6</b>	<b>1.7</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 891,362	\$ 848,806	5.0	4.0	1.0
Diagnostic Systems	836,053	797,405	4.8	4.5	0.3
<b>TOTAL</b>	<b>\$1,727,415</b>	<b>\$1,646,211</b>	<b>4.9</b>	<b>4.3</b>	<b>0.6</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 704,243	\$ 670,283	5.1	7.8	(2.7)
Discovery Labware	229,653	221,300	3.8	5.5	(1.7)
<b>TOTAL</b>	<b>\$ 933,896</b>	<b>\$ 891,583</b>	<b>4.7</b>	<b>7.3</b>	<b>(2.6)</b>
<b>TOTAL REVENUES</b>	<b>\$5,639,857</b>	<b>\$5,263,141</b>	<b>7.2</b>	<b>6.5</b>	<b>0.7</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
SAFETY REVENUES  
(Unaudited; Amounts in thousands)

	Three Months Ended June 30,				
	2010	2009	% Change		
			Reported	FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$277,005	\$272,719	1.6	1.6	—
International	158,764	148,970	6.6	6.5	0.1
<b>TOTAL</b>	<b>\$435,769</b>	<b>\$421,689</b>	<b>3.3</b>	<b>3.3</b>	<b>—</b>
<b>BY SEGMENT</b>					
BD Medical	\$202,714	\$198,642	2.0	1.8	0.2
BD Diagnostics	233,055	223,047	4.5	4.7	(0.2)
<b>TOTAL</b>	<b>\$435,769</b>	<b>\$421,689</b>	<b>3.3</b>	<b>3.3</b>	<b>—</b>
	Nine Months Ended June 30,				
	2010	2009	% Change		
			Reported	FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 844,036	\$ 796,714	5.9	5.9	—
International	464,254	419,768	10.6	7.9	2.7
<b>TOTAL</b>	<b>\$1,308,290</b>	<b>\$1,216,482</b>	<b>7.5</b>	<b>6.6</b>	<b>0.9</b>
<b>BY SEGMENT</b>					
BD Medical	\$ 631,572	\$ 574,984	9.8	8.7	1.1
BD Diagnostics	676,718	641,498	5.5	4.7	0.8
<b>TOTAL</b>	<b>\$1,308,290</b>	<b>\$1,216,482</b>	<b>7.5</b>	<b>6.6</b>	<b>0.9</b>

**Reconciliations of non-GAAP financial measures**  
**(All figures are rounded. Totals may not add up due to rounding)**

**Third quarter and first nine months fiscal year (“FY”) 2009 adjusted diluted earnings per share from continuing operations (“EPS”)**

	<u>Third Quarter</u>	<u>First Nine Months</u>
Reported EPS	\$1.38	\$3.67
Tax benefit (1)	(\$0.08)	(\$0.08)
Litigation charge (2)		<u>\$ 0.11</u>
Adjusted EPS	<u>\$1.30</u>	<u>\$3.70</u>

- (1) Represents the tax benefit relating to various tax settlements in multiple jurisdictions.
- (2) Represents the charge relating to the pending settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in the antitrust class actions.

**Full year FY 2009 adjusted EPS**

Reported EPS	\$ 4.92
Tax benefit (1)	(\$0.08)
Litigation charge (2)	<u>\$ 0.11</u>
Adjusted EPS	<u>\$ 4.95</u>

- (1) Represents the tax benefit relating to various tax settlements in multiple jurisdictions.
- (2) Represents the charge relating to the pending settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in the antitrust class actions.

**First nine months FY 2010 adjusted EPS**

	<u>Second Quarter</u>
Reported EPS	\$3.81
Tax charge (1)	<u>\$0.04</u>
Adjusted EPS	<u>\$3.85</u>

- (1) Represents impact of non-cash charge related to health care reform impacting Medicare Part D reimbursements.
-



**Third quarter FY2010 foreign currency-neutral EPS growth**

	Reported Q3 FY2010	Adjusted Q3 FY2009	Change (\$)	Q3 FY2009 hedge gain	Q3 FY2010 impact of foreign currency translation	Total unfavorable foreign currency impact	Foreign currency neutral growth (\$)	Foreign currency neutral growth (%)
EPS	\$ 1.29	\$ 1.30	(\$0.01)	(\$0.07)	(\$0.02)	(\$0.10)	\$ 0.09	6.9%

**First nine months FY2010 foreign currency-neutral EPS growth**

	FY2010	FY2009	Change (\$)	FY2009 foreign currency holding gain	FY2009 hedge gain	FY2010 impact of foreign currency translation	FY2010 hedge loss	Total unfavorable foreign currency impact	Foreign currency neutral growth (\$)	Foreign currency neutral growth (%)
Adjusted EPS	\$ 3.85	\$ 3.70	\$0.15	(\$0.09)	(\$0.23)	\$ 0.16	(\$0.11)	(\$0.27)	\$ 0.42	11.4%

**FY 2010 EPS Outlook**

	Estimated growth (based on adjusted FY2009 EPS of \$4.95)	Estimated foreign currency neutral growth	Impact of foreign currency translation
EPS guidance — reported	2-3%	8%	- 5%
Tax charge (1)	1%	1%	
EPS guidance — as adjusted	3-4%	9%	- 5%

(1) Represents impact of non-cash charge related to health care reform impacting Medicare Part D reimbursements.

The FY2010 impact of -5% represents the year-on-year change due to estimated foreign currency translation, including hedging activities, as follows:

<b>FY2009 Items:</b>	
Actual hedge gain in FY2009	\$ (0.26)
Q1 FY2009 foreign currency holding gain	\$ (0.09)
<b>FY2010 Activity: *</b>	
Estimated favorable effect of foreign currency translation	\$ 0.15
Estimated hedge losses	\$ (0.06)
<b>Total Year-on-Year Impact</b>	<b>\$ (0.26)</b>
Impact on EPS Growth	\$ (0.26)/\$4.95 ~ - 5%

\* Estimated impact is based on the foreign exchange rates established for BD's most recent fiscal year 2010 projection.